Pubmed- Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis. - IBD Reporter Newsfeed - IBD Support Group Forums - IBDsupport.org

Advertisement

Jump to content


Photo
- - - - -

Pubmed- Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis.


  • Please log in to reply
No replies to this topic

#1 Health Reporter

Health Reporter

    Newsfeeder

  • RSS
  • PipPipPipPip
  • 20578 posts
  • Country:United States

Posted 08 January 2021 - 01:36 AM

Advertisement
Icon for PubMed Central Related Articles

Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis.

Ther Adv Musculoskelet Dis. 2020;12:1759720X20969261

Authors: Petitdemange A, Blaess J, Sibilia J, Felten R, Arnaud L

Abstract
Background: Pathogenic inflammatory pathways are largely shared between different autoimmune and inflammatory diseases (AIDs). This offers the potential to develop a given targeted therapy in several AIDs.
Methods: We analyzed two clinical trials registries (ClinicalTrials.gov and EU Clinical Trials Register) to identify the targeted therapies whose development is shared between at least two of the most common AIDs [rheumatoid arthritis (RA), spondyloarthritis (SpA), cutaneous psoriasis (cPso), inflammatory bowel diseases (IBD), systemic lupus erythematosus (SLE), primary Sjgren's syndrome (pSS), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), giant cell arteritis (GCA), and multiple sclerosis (MS)] using an in-depth repurposing analysis.
Results: We identified 142 shared targeted therapies. The four diseases in which shared targeted therapies were the most numerous were RA (n = 92), cPso (n = 67), IBD (n = 58), and SLE (n = 56). The two clusters of diseases between which the overlap of targeted therapies was the most important were RA and SLE as well as RA, SpA, cPso, and IBD. The targeted therapies which were shared by five diseases or more were abatacept, ustekinumab, rituximab, anakinra, etanercept, infliximab, secukinumab, tofacitinib, alemtuzumab, tocilizumab, adalimumab, apremilast, baricitinib, belimumab, brodalumab, filgotinib, and upadacitinib. The most frequently targeted molecules and pathways were (by descending frequency): JAK-STAT pathways, Th17 axis, TNF-α, IL-6, costimulation molecules, BAFF, CD20, BTK, chemokines and integrins, IL-1, and type I interferon.
Conclusion: Many targeted therapies are developed in several AIDs, reflecting the overlap of pathogenic pathways and potential of drug repurposing. This suggests that a revision of the current, clinically based classification of AIDs towards a more mechanistic-based taxonomy might be relevant.

PMID: 33403021 [PubMed]



View the full article


Advertisement




© Copyright 1995-2014 IBD Support All rights reserved.

About Us | Contact Us | Advertise With Us | Disclaimer | Terms of Service | Crisis Resources

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information: verify here